Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SNAI1 cis-regulatory enhancer RNA expressed in monocytes 1 (SCREEM1) is a type of enhancer RNA (eRNA), and more specifically a long non-coding RNA (lncRNA), transcribed from a locus near the SNAI1 gene. It forms part of the SCREEM locus, which consists of several eRNAs (including SCREEM1, SCREEM2, and SCREEM3) specifically expressed in monocytes. Activation of SCREEM1 leads to increased expression of the adjacent SNAI1 gene, a master transcriptional regulator of the epithelial-mesenchymal transition (EMT). The SCREEM-SNAI1 axis thus highlights a cis-regulatory mechanism in which non-coding RNAs mark super-enhancer regions that tightly control gene expression programs central to cell identity and behavior. While SCREEM1 itself is not established as a direct therapeutic target and its transcripts are dispensable for SNAI1 induction, its locus acts as a regulatory hub; exploration of this region may offer insights into EMT, cancer progression, immune cell biology, and potentially the pathogenesis of acute monocytic leukemia. No drugs, mechanisms of action, or biomarkers directly involving SCREEM1 have been described to date[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SNAI1 cis-regulatory enhancer RNA expressed in monocytes 1 (SCREEM1).